Project Grant R21AI177237
Award Date 9/9/25
Completion Date 8/31/27
Dollars Obligated $849K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded $234,000 to the University of Maryland, College Park on May 26, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to support research into phagosomal membrane repair pathways during Mycobacterium tuberculosis infection using high-throughput single-cell and single-phagosome analysis. The research deciphers how host cell machinery repairs damage to the mycobacterium-containing vacuole, a process critical...
- The National Institute of Allergy and Infectious Diseases, a division of the Department of Health and Human Services, awarded the University of Maryland, Baltimore $312,537 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 1, 2026, to support the Mechanisms Integrating Nervous and Immune Systems Training Program (MINISTP). The award funds a two-tiered training curriculum designed to prepare three graduate students and two post-doctoral researchers for up to...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases awarded a cooperative agreement totaling $634,247 to the University of Maryland, Baltimore on July 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the role of penicillin-binding protein 4 (PBP4) in mediating antibiotic resistance and pathogenesis of Staphylococcus aureus. The research investigates how PBP4-mediated mutations enable high-level, broad-spectrum β-lactam...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $678,218 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct multi-omics analysis of bacteria-host interactions in Brugia malayi, a filarial nematode that harbors obligate Wolbachia endosymbionts. The research examines the molecular underpinnings of the symbiosis between filarial nematodes and their Wolbachia bacterial endosymbionts, with...
- The National Institute of Allergy and Infectious Diseases awarded $233,250 to the University of Maryland, Baltimore on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to fund research on how Rickettsia species manipulate macrophage antimicrobial responses through engagement of the CD300F efferocytic receptor to facilitate host infection. The research addresses the gap in understanding rickettsial pathogenesis mechanisms that has hindered development of...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of Maryland, Baltimore $136,988 under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct investigator-initiated biomedical research on Enterovirus D68 (EV-D68) infection mechanisms. The award, obligated on August 20, 2025, with a project completion date of July 31, 2027, supports research designed to advance scientific understanding of how transcription...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $127,932 on March 18, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate neuraminidase as a target antigen for a universal influenza virus vaccine. The research addresses the gap between current seasonal influenza vaccines, which elicit only strain-specific immunity with variable effectiveness and provide no protection against novel pandemic...
- The National Institute of Allergy and Infectious Diseases, a component of the Department of Health and Human Services, awarded $148,614 to Massachusetts Institute of Technology on January 14, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will develop glycopolymers designed to enhance interactions between immune cells and pathogenic bacteria, creating "cellular glues" that leverage the body's innate immune mechanisms as an alternative to...